PART TWO
Diagnostic Cytology
452. Lin F, Shen T, Prichard JW. Detection of
Her2/neu oncogene in breast carcinoma
by chromogenic in situ hybridization in
cytologic specimens.
Diagn Cytopathol
2005;33:376-380.
453. Zhao J, Wu R, Au A, et al. Determination
of HER2 gene amplification by chro-
mogenic in situ hybridization (CISH) in
archival breast carcinoma. Mod Pathol
2002;15:657-665.
454. Bozzetti C, Nizzoli R, Camisa R, et al.
Comparison between Ki-67 index and S-
phase fraction on fine-needle aspiration
samples from breast carcinoma.
Cancer
(Cancer Cytopathol)
1997;25:287-292.
455. Lee AKC, Dugan J, Hamilton WM,
et al. Quantitative DNA analysis in
breast carcinomas: a comparison
between image analysis and flow cytom-
etry.
Mod Pathol
1991;4:178-182.
456. Lajoie G, Zbieranowski I, Demianiuk C.
A comparative study of DNA quantita-
tion in breast carcinoma with image cyto-
metric analysis and
in vitro
fine-needle
aspiration with flow cytometric analysis.
Am J Clin Pathol
1993;100:456-462.
457. Kuenen-Boumeester V, Kwast THVD,
Laarhoven HAJV, et al. Ki-67 staining in
histological subtypes of breast carci-
noma and fine needle aspiration smears.
J Clin Pathol
1991;44:208-210.
458. Van Zee KJ, Ortega PĂ©rez G, Minnard
E, et al. Preoperative galactography
increases the diagnostic yield of major
duct excision for nipple discharge.
Cancer
(Cancer Cytopathol)
1998;82:1874-1880.
459. Johnson Tl, Kini SR. Cytologic and
clinicopathologic features of abnormal
nipple secretions: 225 cases.
Diagn
Cytopathol
1991;7:17-22.
460. Takeda T, Matsui A, Sato Y, et al.
Nipple discharge cytology in mass
screening for breast cancer.
Acta Cytol
1990;34:161-164.
461. Carty NJ, Royle GT, Mudan SS, et al.
Prospective study of outcome in women
presenting with nipple discharge.
Ann R
Coll Surg Engl
1994;76:387-389.
462. Leis HP. Management of nipple dis-
charge.
Br J Clin Pract
1989;68:58-65.
463. Ujevich B, Saad RS, Liu YL, et al. Abnor-
mal nipple discharge: cytohistological
correlation.
Acta Cytol
2003;47:861A.
464. Ciatto S, Bravetti P, Cariagg P. Sig-
nificance of nipple discharge clini-
cal patterns in the selection of cases
for cytologic examination.
Acta Cytol
1986;30:17-20.
465. Das DK, Al-Ayadhy B, Ajrawi MT,
et al. Cytodiagnosis of nipple discharge:
a study of 602 samples from 484 cases.
Diagn Cytopathol
2001;25:25-37.
466. Dunn jM, Lucarotti ME, Wood SJ, et al.
Exfoliative cytology in the diagnosis of
breast disease.
Br J Surg
1995;82:789-791.
467. Krishnamurthy S, Sneige N, Ordonez
NG, et al. Characterization of foam cells
in nipple aspirate fluid.
Diagn Cytopathol
2002;27:261-264.
468. Dupont WD, Parl FF, Hartmann WH,
et al. Breast cancer risk associated with
proliferative breast disease and atypical
hyperplasia.
Cancer (Cancer Cytopathol)
1993;71:1258-1265.
469. Fabian CJ, Kimler BF, Zalles CM, et al.
Short-term, breast cancer prediction by
random periareolar fine needle aspira-
tion cytology and the Gail risk model.
J
Natl Cancer Inst
2000;92:1217-1227.
470. Vogel V. Atypia in the assessment of breast
cancer risk: implications for management.
Diagn Cytopathol
2004;30:151-157.
471. Wrensch Mr, Petrakis NL, King EB, et
al. Breast cancer incidence in women
with abnormal cytology in nipple
aspirates of breast fluid.
Am J Epidemiol
1992;135:130-141.
472. Dooley WC, Ljung BM, Veronesi U, et al.
Ductal lavage for detection of cellular aty-
pia in women at high risk for breast cancer.
J Natl Cancer Inst
2001;93:1624-1632.
473. Higgins SA, Matloff ET, Rimm DL, et al.
Patterns of reduced nipple aspirate fluid
production and ductal lavage cellularity
in women at high risk for breast cancer.
Breast Cancer Res
2005;7:R1017-R1022.
474. O'Shaughnessy J. Ductal lavage. In:
Vogel VG, Bevers T (eds)
Handbook of
Breast Cancer Risk Assessment: Evidence-
based Guidelines for Evaluation, Prevention,
Counseling, and Management.
Boston:
Jones and Bartlett, 2004p 66-79.
475. O'Shaughnessy JA, Ljung BM, Dooley
WC, et al. Ductal lavage and the clinical
management of women at high risk for
breast carcinoma: a commentary.
Cancer
(Cancer Cytopathol)
2002;94:292-298.
476. Antill YC, Mitchell G, Johnson SA, et al.
Loss of heterozygosity analysis in ductal
lavage samples from BRAC1 and BRAC2
carriers: cautionary tale.
Cancer Epidemiol
Biomarkers Prev
2006;15:1396-1398.
477. Locke I, Kote-Jarari Z, Bancroft E, et al.
Loss of heterozygosity at the BRAC1
and BRAC2 loci detected in ducal lavage
fluid from BRAC gene mutation carriers
and controls.
Cancer Epidemiol Biomark-
ers Prev
2006;15:1399-1402.
478. Lawler M, Newton A, Levin E, et al.
Cytologic evaluation of duct washings
does not reliably detect lactiferous duct
pathology.
Breast Cancer Res
2001;69:297.
479. Brogi E, Robson M, Panageas KS, et al.
Ductal lavage in patients undergoing
mastectomy for mammary carcinoma:
a correlative study.
Cancer (Cancer
Cytopathol)
2003;98:2170-2176.
480. Arun B. Ductal lavage and risk assess-
ment of breast cancer.
Oncologist
2004;9:599-605.
481. Badve S. Ductal lavage and its his-
topathologic basis: a cautionary tale.
Diagn Cytopathol
2004;30:166-171.
482. Ljung B-M, Chew KL, Moore DH,
et al. Cytology of ductal lavage fluid of
the breast.
Diagn Cytopathol
2004;30:143-150.
483. Abati A, Greene MH, Filie A, et al.
Quantification of the cellular compo-
nents of breast duct lavage samples
[letter to the editor].
Diagn Cytopathol
2005;34:78-81.
772
previous page 763 ComprehensiveCytopathology 1104p 2008 read online next page 765 ComprehensiveCytopathology 1104p 2008 read online Home Toggle text on/off